A Synergistic Approach in the Pre-Clinical Phase of Dementias

Vascular dementia and Alzheimer’s disease share a decades-long asymptomatic pre-clinical phase. This review proposes combining anodal HD-tDCS neuromodulation with structured vascular protection to intervene during the neuroimaging-identified therapeutic window. Vascular protection arrests structural lesion progression; HD-tDCS recruits cortical excitability, induces LTP, upregulates BDNF, and rehabilitates chronic ischaemic penumbra. Rigorous randomised controlled trials are urgently needed to validate this proactive paradigm.

1. INTRODUCTION AND THE PRE-CLINICAL WINDOW OF OPPORTUNITY

1.1 The Asymptomatic Phase of Dementias: An Underestimated Paradigm

Dementias represent a spectrum of neurodegenerative and cerebrovascular syndromes whose global epidemiological impact constitutes one of the major public health crises of the twenty-first century. World Health Organization estimates point to over 55 million individuals affected in 2023, with projections indicating a doubling of this number by 2050, driven by accelerated population ageing. Among the most prevalent aetiologies, Alzheimer's Disease (AD) and Vascular Dementia (VD) stand out, frequently coexisting in a pattern of mixed dementia, sharing common pathological substrate in small cerebral vessel lesions.

Critically, both AD and VD present an asymptomatic pre-clinical phase estimated to last between one and three decades, during which molecular and structural pathological processes evolve silently and progressively, well before the clinical manifestation of cognitive impairment. In AD, cerebral amyloid deposition precedes the clinical diagnosis by approximately 15 to 20 years; in VD, the accumulation of silent microinfarcts and periventricular white matter rarefaction begins decades before measurable cognitive decline. This observation demands a fundamental revision of the prevailing therapeutic paradigm, which has historically concentrated on managing symptomatic stages, when neuronal loss is already substantial and functional recovery capacity severely compromised.

1.2 The Therapeutic Window of Opportunity: Definition and Rationale

The concept of "Therapeutic Window of Opportunity" refers to the time interval during which structural brain alterations are already detectable by advanced neuroimaging methods — such as high-resolution Magnetic Resonance Imaging (3T MRI), FLAIR sequences for white matter lesions, and cortical volumetry techniques via voxel-based morphometry (VBM) — yet precede clinically consolidated cognitive decline. Within this window, the remaining neuronal parenchyma retains potential for plasticity and functional reorganisation, and modifiable risk factors still exert a reversible impact on the progression of vascular lesions.

From a clinical and neuroimaging perspective, this window is identified when the patient presents: (i) initial brain volumetric reduction, particularly of the hippocampus, entorhinal cortex, and prefrontal regions, with Z-scores between −1.0 and −1.5 standard deviations from age-normative values; (ii) periventricular and/or subcortical White Matter Hyperintensities (WMH), classified on Fazekas scales grades 1–2; (iii) silent cerebral microinfarcts, identifiable on high-resolution DWI and SWI sequences; and (iv) absence or only initial presence of subjective cognitive complaints (SCC), without criteria for established Mild Cognitive Impairment (MCI).

It is precisely in this interval that neuromodulatory and neuroprotective interventions hold the greatest potential for disease-course modification. Late intervention, after consolidation of MCI or a diagnosis of mild dementia, encounters a significantly reduced neuronal substrate with compromised functional connectivity and exhausted cognitive reserve, dramatically limiting the efficacy of any therapeutic strategy.

2. MECHANOPATHOLOGY: THE SILENT NEUROVASCULAR DECLINE

2.1 Silent Cerebral Microinfarcts and the Cumulative Ischaemic Cascade

Silent cerebral microinfarcts (SCMs) constitute ischaemic lesions of microscopic to mesoscopic dimensions — typically below 1 cm in diameter — occurring without detectable acute clinical correlates. Their pathogenesis relates primarily to Small Vessel Disease (SVD), characterised by degenerative changes in the wall of penetrating arterioles and cerebral capillaries, including lipohyalinosis, cerebral amyloid angiopathy, arteriolosclerosis, and progressive endothelial dysfunction. Occlusion of small penetrating arteries (50–200 μm calibre) results in foci of ischaemic necrosis which, individually, may produce no focal neurological deficit, yet whose progressive accumulation over years to decades imposes a cumulative lesion burden with devastating consequences upon neural network integrity.

At the cellular level, focal ischaemia triggers a well-established pathological cascade: oxygen and glucose deprivation causes mitochondrial ATP depletion, with consequent failure of energy-dependent ionic pumps — notably Na⁺/K⁺-ATPase and Ca²⁺-ATPase. The massive intracellular Ca²⁺ influx activates proteases, phospholipases, and endonucleases, resulting in neuronal death by necrosis and, in perilesional ischaemic penumbra regions, by delayed apoptosis. Resident microglia and astrocytes react with a local inflammatory response, releasing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and reactive oxygen species, which amplify tissue damage to surrounding parenchyma, expanding the effective lesion radius beyond the primary ischaemic core.

The neuronal loss resulting from these cumulative ischaemic events constitutes the direct pathological substrate of the brain volumetric reduction observed on neuroimaging. The death of cortical and subcortical neurons, combined with Wallerian degeneration of axonal pathways and dendritic volume loss, translates macroscopically into measurable regional atrophy. Particularly vulnerable regions include the hippocampus, subcortical nuclei, the thalamus, and periventricular white matter, in which the network of terminal penetrating arteries confers inherent vulnerability to ischaemia.

2.2 Neurovascular Coupling Failure: The Physiopathological Bottleneck

Neurovascular Coupling (NVC) refers to the fundamental physiological mechanism by which local neuronal activity signals and coordinates a corresponding increase in regional cerebral blood flow (rCBF), ensuring adequate supply of oxygen and glucose to the metabolic demands of active neurons — the physiological basis of functional neuroimaging (fMRI-BOLD). This process involves an integrated communication network among neurons, astrocytes, pericytes, and endothelial cells of the neurovascular unit, mediated by vasoactive molecules including nitric oxide (NO), prostaglandins, extracellular K⁺, and arachidonic acid.

In Small Vessel Disease, NVC is profoundly compromised by multiple converging mechanisms. Arterial and arteriolar stiffness, resulting from lipohyalinosis and hyaline material deposition in the vascular wall, reduces vessel compliance and restricts vasodilatory capacity in response to neuronal activity. Endothelial dysfunction — characterised by reduced expression of endothelial nitric oxide synthase (eNOS), increased oxidative stress, and activation of pro-inflammatory pathways — further compromises endothelium-mediated vasodilatory mechanisms. The loss of pericytes removes an additional level of rCBF control at the microangiopathic level.

The functional consequences of NVC failure are considerable. Neurons that remain structurally intact, but whose vascular territory cannot respond adequately to increased metabolic demand during cognitive activation, enter a state of chronic functional hypometabolism — demonstrable by FDG-PET as reduced glucose metabolism. This state of "chronic metabolic penumbra" represents a substrate of reversible neuronal dysfunction that, in the absence of intervention, progressively evolves towards irreversible structural injury.

3. HD-TDCS NEUROMODULATION AS A RESCUE MECHANISM

3.1 Electrophysiological Foundations: Membrane Potential Modulation

High-Definition transcranial Direct Current Stimulation (HD-tDCS) is a non-invasive neuromodulation technique that applies low-intensity electrical current (typically 1–2 mA) through a 4×1 ring electrode montage positioned over cortical target regions, inducing subthreshold changes in the resting membrane potential of underlying neurons with greater spatial focality than conventional tDCS. The HD configuration — a central active electrode surrounded by four return electrodes forming an outer ring — produces a focal intracranial electric field demonstrably superior in spatial precision. Anodal stimulation causes partial neuronal membrane depolarisation, bringing the membrane potential closer to the firing threshold and consequently increasing cortical excitability; cathodal stimulation produces hyperpolarisation and reduced excitability.

The primary mechanism of action of anodal HD-tDCS involves the modulation of voltage-gated Na⁺ and Ca²⁺ channels, whose opening is facilitated by the partial depolarisation induced by the current. The modulated Ca²⁺ influx — distinct from the pathological, excitotoxic influx of acute ischaemia — acts as an intracellular second messenger, activating Ca²⁺/calmodulin-dependent signalling pathways that sustain activity-dependent synaptic neuroplasticity processes. Additionally, anodal current modulates NMDA (N-methyl-D-aspartate) receptor activity, reducing voltage-dependent Mg²⁺ ion blockade and facilitating glutamatergic synaptic conduction — a central mechanism in LTP induction and the strengthening of active synapses.

3.2 Induced Neuroplasticity: LTP, BDNF, and Glutamatergic Modulation

The neuroplastic effects of HD-tDCS extend beyond the immediate duration of stimulation, producing persistent changes in synaptic efficacy through mechanisms analogous to Long-Term Potentiation (LTP) — the cellular substrate of learning and memory. LTP induced by HD-tDCS involves the phosphorylation and increased membrane expression of AMPA receptors at the postsynaptic membrane, as well as structural modifications of dendritic spines that broaden the synaptic contact surface. Studies in animal models and humans have consistently demonstrated that anodal HD-tDCS potentiates LTP induction when combined with synaptic stimulation protocols, suggesting a cortical excitability priming effect.

Brain-Derived Neurotrophic Factor (BDNF), a member of the neurotrophin family, represents a critical molecular mediator of HD-tDCS neuroplastic effects. Anodal stimulation promotes increased expression and release of BDNF in stimulated cortical regions via activation of the TrkB receptor. Released BDNF acts in an autocrine and paracrine manner, activating intracellular signalling pathways — including PI3K/Akt/mTOR and RAS/MAPK/ERK — that promote neuronal survival, axonal and dendritic growth, synaptogenesis, and consolidation of LTP-induced synaptic modifications. In elderly populations and cognitive decline models, where basal BDNF expression is frequently reduced, the HD-tDCS-induced increase acquires additional neuroprotective relevance.

The modulation of glutamatergic transmission by HD-tDCS presents characteristics of particular relevance in the context of chronic metabolic penumbra. The modulated and controlled facilitation of glutamatergic neurotransmission in regions of chronic hypometabolism may restore compromised activation thresholds, reintegrating functional circuits that had entered a state of compensatory synaptic silence.

3.3 Neurovascular Effects: Cerebral Blood Flow and Penumbra Rehabilitation

Beyond its direct neural effects, HD-tDCS exerts documented influence over regional cerebral haemodynamics. Transcranial Doppler, arterial spin labelling (ASL) by functional MRI, and near-infrared spectroscopy (fNIRS) studies have consistently demonstrated that anodal stimulation induces a transient increase in rCBF in electrode-underlying regions, with magnitude varying between 10% and 30% above baseline values during and immediately after stimulation.

Proposed mechanisms for this vasoactive effect include: (i) increased local nitric oxide (NO) production by neurons and endothelial cells, with consequent arteriolar vasodilation mediated by soluble guanylate cyclase; (ii) neuronal activity modulation with NVC increment in stimulated regions; and (iii) direct effects upon vascular endothelium and pericytes, facilitating the vasodilatory response. The capacity of HD-tDCS to increase rCBF in regions with compromised NVC represents a mechanism of functional rehabilitation of neurons in chronic metabolic penumbra, supplying the energetic substrate necessary for the expression of stimulation-induced neuroplasticity phenomena.

4. THE VASCULAR PROTECTION PILLAR AND THERAPEUTIC SYNERGY

4.1 The Limitations of Isolated Neuromodulation

Despite its promising mechanism of action and positive Phase I and II study results, HD-tDCS faces structural limitations that circumscribe its efficacy when applied to a progressively compromised cerebrovascular substrate. The therapeutic efficacy of any neuromodulatory intervention is inherently dependent on the integrity of the parenchyma over which it acts: neurons in a state of severe metabolic dysfunction, deprived of adequate vascular supply and surrounded by inflammatory and gliotic tissue, respond in an attenuated or unpredictable manner to exogenous electrical stimulation.

More critically, if Small Vessel Disease continues to progress without intervention upon its determinant factors, the rate of new silent microinfarct generation and white matter lesion expansion will exceed the capacity for neuroplastic compensation induced by HD-tDCS. Longitudinal studies in populations with active SVD demonstrate rates of new WMH foci emergence between 5% and 15% per year, with microinfarct accumulation imposing continuous neuronal loss. In this scenario, HD-tDCS would act as a moving baseline intervention — attempting to optimise the function of a structurally deteriorating neural network — without addressing the root cause of progressive damage.

4.2 Vascular Protection Strategies: The Structural Foundation

Cerebral vascular protection comprises an integrated set of interventions directed at the principal modifiable risk factors and the pathogenic mechanisms of microvascular injury. Rigorous control of Systemic Arterial Hypertension (SAH) occupies a central position, as SAH constitutes the most prevalent individual risk factor most strongly associated with SVD. Meta-analyses of clinical trials demonstrate that reduction of systolic blood pressure to targets below 130 mmHg reduces the incidence of vascular dementia by approximately 38% in high-risk populations.

Rigorous glycaemic control in the context of Type 2 Diabetes Mellitus (T2DM) is equally fundamental, given the role of chronic hyperglycaemia in promoting endothelial dysfunction, formation of Advanced Glycation End-products (AGEs), vascular oxidative stress activation, and impairment of endothelial NO synthesis. HbA1c targets below 7%, associated with the preferential use of agents with demonstrated neuroprotective effects — such as GLP-1 analogues and SGLT-2 inhibitors — constitute the current approach of choice. Dyslipidaemia treatment, with emphasis on LDL-cholesterol reduction through high-intensity statins, reduces atherosclerotic burden and systemic vascular inflammation, with benefits in preserving cerebral endothelial integrity.

Antiplatelet therapy — with low-dose acetylsalicylic acid (75–100 mg/day) or clopidogrel in intolerant patients — plays a relevant role in microembolism prevention in patients with established SVD and elevated thrombotic risk profile. Its indication must be individualised by haemorrhagic risk, particularly in patients with extensive leukoaraiosis.

4.3 Physical Exercise: Angiogenesis, Neurogenesis, and Neuroprotection

Regular aerobic physical exercise represents one of the non-pharmacological interventions with the most robust evidence base for cerebrovascular health and cognitive decline prevention. At the vascular level, moderate-intensity aerobic exercise (50–70% of VO₂max, 150 minutes weekly) promotes cerebral angiogenesis via VEGF-dependent mechanism, increasing cerebral capillary density and improving regional perfusion. This angiogenic effect is particularly relevant in the hippocampus, where adult neurogenesis is stimulated by exercise via BDNF-, IGF-1-, and serotonin-dependent mechanisms.

The combination of physical exercise with HD-tDCS sessions presents first-order synergistic potential: exercise elevates circulating and central BDNF levels, creates a state of greater cortical excitability and synaptic plasticity facilitation, while subsequent anodal HD-tDCS capitalises on this state of neurobiological "priming" to induce more durable and higher-amplitude synaptic modifications. This hypothesis, termed "metabolic-neuromodulatory priming," finds support in preliminary studies demonstrating greater magnitude of cognitive effects when exercise precedes HD-tDCS in combined protocols.

4.4 Therapeutic Synergy: Rationale for the Dual Protocol

The central justification for the proposed synergistic approach lies in the mechanistic and temporal complementarity of the two intervention pillars. Vascular protection acts primarily as a "progression containment" strategy — reducing the rate of new microinfarct generation, stabilising the vascular substrate, and preserving neurovascular unit integrity. It "freezes" or significantly decelerates the progression of structural lesions, ensuring that existing neuronal parenchyma is preserved and that minimum metabolic supply conditions for synaptic function are maintained.

HD-tDCS, in turn, acts upon the neuronal substrate preserved by vascular protection, optimising its functional performance. Through the neuroplasticity mechanisms described — LTP, BDNF expression, NMDA receptor modulation, synaptic strengthening — stimulation recruits and potentiates the Cognitive Reserve of surviving neurons, increasing the efficiency of existing neural networks and potentially facilitating the recruitment of alternative processing routes that compensate for circuits damaged by microinfarcts.

The concept of Cognitive Reserve — defined as the brain's capacity to utilise alternative neural networks and to increase processing efficiency to compensate for structural damage — is central to understanding the mechanism by which HD-tDCS can delay the clinical manifestation of cognitive decline even in a brain with existing structural lesions. Epidemiological studies consistently demonstrate that individuals with greater cognitive reserve manifest clinically apparent cognitive decline with greater structural lesion burden than individuals with lesser reserve. HD-tDCS can be conceived as a mechanism of amplification and maintenance of this reserve at the neurophysiological level.

5. CONCLUSION AND FUTURE DIRECTIONS

5.1 Synthesis: A Paradigm Shift from Preventive to Proactive

The synergistic approach outlined in this review represents a conceptual inflection of fundamental relevance in the field of dementias: the transition from an essentially preventive paradigm — focused on risk factor mitigation without active intervention on the neural substrate — to a proactive paradigm, combining structural protection of brain parenchyma with active stimulation of neuroplasticity and cognitive reserve mechanisms during the pre-clinical window of opportunity.

The convergence of three lines of evidence confers robust plausibility to this approach: (i) the demonstration, by longitudinal neuroimaging, that structural lesions of SVD precede clinically apparent cognitive decline by decades, identifying an objectively measurable intervention window; (ii) the establishment of molecular and physiological mechanisms by which HD-tDCS modifies cortical excitability, neuroplasticity, and regional cerebral haemodynamics; and (iii) evidence that vascular risk factor control, particularly arterial hypertension, significantly reduces SVD lesion progression and vascular dementia risk.

References

1. Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol. 2000;527(3):633–639. doi:10.1111/j.1469-7793.2000.t01-1-00633.x
   2. Bikson M, Grossman P, Thomas C, et al. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016;9(5):641–661. doi:10.1016/j.brs.2016.06.004
   3. Caparelli-Dáquer EM, Zimmermann TJ, Mooshagian E, Parra LC, Rice JK, Datta A, et al. A pilot study on effects of 4×1 HD-tDCS on motor cortex excitability. Conf Proc IEEE Eng Med Biol Soc. 2012:735–738. [Author’s prior work — NYC Neuromodulation Conference 2018]
   4. Dichgans M, Leys D. Vascular Cognitive Impairment. Circ Res. 2017;120(3):573–591. doi:10.1161/CIRCRESAHA.116.308426
   5. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18(7):684–696. doi:10.1016/S1474-4422(19)30079-1
   6. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–838. doi:10.1016/S1474-4422(13)70124-8
   7. Iadecola C. The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. Neuron. 2017;96(1):17–42. doi:10.1016/j.neuron.2017.07.030
   8. Brunoni AR, Nitsche MA, Bolognini N, et al. Clinical Research with Transcranial Direct Current Stimulation (tDCS): Challenges and Future Directions. Brain Stimul. 2012;5(3):175–195. doi:10.1016/j.brs.2011.03.002
   9. Terranova C, Rizzo V, Cacciola A, et al. Is There a Future for Non-invasive Brain Stimulation as a Therapeutic Tool? Front Neurol. 2019;9:1146. doi:10.3389/fneur.2018.01146
   10. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–446. doi:10.1016/S0140-6736(20)30367-6
   11. van der Flier WM, Skoog I, Schneider JA, et al. Vascular cognitive impairment. Nat Rev Dis Primers. 2018;4:18003. doi:10.1038/nrdp.2018.3
   12. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA. 2011;108(7):3017–3022. doi:10.1073/pnas.1015950108
   13. Spriggs MJ, Bhakta M, Bhakta S, et al. Transcranial direct current stimulation (tDCS) to enhance cognitive function in older adults: a systematic review and meta-analysis. Neuropsychol Rehabil. 2021;31(7):1073–1108. doi:10.1080/09602011.2019.1703290
   14. Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007;30(9):464–472. doi:10.1016/j.tins.2007.06.011
   15. SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia. JAMA. 2019;321(6):553–561. doi:10.1001/jama.2018.21442
   16. Bangen KJ, Nation DA, Clark LR, et al. Aggregate effects of vascular risk factors on cerebrovascular changes and cognition in older adults. Alzheimers Dement. 2017;13(10):1136–1144. doi:10.1016/j.jalz.2017.02.010
   17. Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol. 2012;11(11):1006–1012. doi:10.1016/S1474-4422(12)70191-6
   18. Koenig T, Prichep L, Dierks T, et al. Decreased EEG synchronization in Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging. 2005;26(2):165–171. doi:10.1016/j.neurobiolaging.2004.03.008
   19. Nichols E, Steinmetz JD, Vollset SE, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105–e125. doi:10.1016/S2468-2667(21)00249-8
   20. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505–522. doi:10.1038/s41569-018-0064-2